What is the actual reimbursement cost of Osimertinib/Tagressa after medical insurance reimbursement?

Osimertinib/Tagrisso (Osimertinib) is a targeted drug targeting EGFR mutations and is mainly used to treat non-small cell lung cancer (NSCLC). With its launch in the Chinese market and the implementation of its inclusion in medical insurance policies, the financial burden on patients has been significantly alleviated.

Before osimertinib is included in medical insurance, its market price usually reaches RMB 4,000 to 6,000 per box. The specific price varies according to the specifications of the drug and the sales policies of different regions. When this targeted drug is included in medical insurance, patients can enjoy the benefits brought by medical insurance reimbursement, and the actual expenses paid are significantly reduced. According to relevant policies, when patients purchase osimertinib, they can reimburse part of the cost through medical insurance. The specific reimbursement ratio will vary depending on the region and the patient's medical insurance type. For the vast majority of patients, this means a significant reduction in the financial stress of receiving treatment, allowing more patients to have access to this important treatment.

In addition to its price advantage, osimertinib’s effectiveness and tolerability are also the reasons why it is widely recognized. In clinical trials, osimertinib has shown good efficacy, especially against non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation or T790M mutation. Therefore, even if the price is adjusted, the clinical value of osimertinib cannot be ignored. When patients receive treatment, they not only pay attention to the price of the drug, but also pay more attention to the effect of the treatment and the improvement of their quality of life. When using drugs, patients should have regular follow-up visits and maintain good communication with their doctors so that the treatment plan can be adjusted in a timely manner.

Reference materials:https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/osimertinib